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Abstract
PD-L1 antibodies produce efficacious clinical responses in diverse human cancers, but the basis 
for their effects remains unclear, leaving a gap in understanding of how to rationally leverage the 
therapeutic activity. PD-L1 is widely expressed in tumor cells but its contributions to tumor 
pathogenicity are incompletely understood. In this study, we evaluated the hypothesis that PD-L1 
exerts tumor cell-intrinsic signals that are critical for pathogenesis. Using RNAi methodology, we 
attenuated PD-L1 in the murine ovarian cell line ID8agg and the melanoma cell line B16 (termed 
PD-L1lo cells), which express basal PD-L1. We observed that PD-L1lo cells proliferated more 
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weakly than control cells in vitro. As expected, PD-L1lo cells formed tumors in 
immunocompetent mice relatively more slowly, but unexpectedly, they also formed tumors more 
slowly in immunodeficient NSG mice. A comparative microarray analysis identified a number of 
genes involved in autophagy and mTOR signaling that were affected by PD-L1 expression. In 
support of a functional role, PD-L1 attenuation augmented autophagy and blunted the ability of 
autophagy inhibitors to limit proliferation in vitro and in vivo in NSG mice. PD-L1 attenuation 
also elevated mTORC1 activity and augmented the anti-proliferative effects of the mTORC1 
inhibitor rapamycin. PD-L1 cells were also relatively deficient in metastasis to the lung and we 
found that anti-PD-L1 administration could block tumor cell growth and metastasis in NSG mice. 
This therapeutic effect was observed with B16 cells but not ID8agg cells, illustrating tumor- or 
tissue-specific effects in the therapeutic setting. Overall, our findings extend understanding of PD-
L1 functions, illustrate non-immune effects of anti-PD-L1 immunotherapy and suggest broader 
uses for PD-L1 as a biomarker for assessing cancer therapeutic responses.
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Introduction
PD-L1 (B7-H1, CD274), an immune co-signaling molecule in the B7-H (B7 homology) 
family (1), negatively regulates T cell functions through PD-1 and CD80 interactions (2), 
and is immunopathogenic in diverse cancers (3). Anti-PD-L1 monoclonal antibodies (αPD-
L1) are clinical efficacy against distinct cancers where the principal mechanism of action is 
thought to be protecting PD-1-expressing anti-tumor T cells from inhibition by tumor PD-L1 
(3–7). αPD-L1 is FDA-approved for bladder cancer. αPD-1 was recently FDA-approved to 
treat melanoma, renal cell carcinoma, non-small cell lung cancer and head and neck cancers. 
It is also proposed to work by protecting PD-1-expressing anti-tumor T cells from inhibition 
by tumor surface-expressed PD-L1, among other potential mechanisms (7,8).
Because of the promise of αPD-L1 and αPD-1 immunotherapy, much attention has focused 
on effects of the tumor PD-L1/T cell PD-1 axis in cancer immunotherapy and 
immunopathogenesis. Following the initial report that tumor PD-L1 kills anti-tumor T cells 
(4), most work on PD-L1 signals in cancer has focused on tumor-extrinsic PD-L1 effects, 
particularly on T cells. However, recent work shows that tumor PD-L1 prevents tumor 
apoptosis (9), reduces chemotherapy-mediated killing by altering mitogen activated protein 
kinase signals (10) and regulates tumor glucose metabolism in sarcomas (11). Thus, tumor 
PD-L1 has important tumor-intrinsic signaling and survival effects, but these are little 
studied.
In our studies of αPD-L1 immunotherapy we used RNAi technology to engineer low PD-
L1-expressing tumors cells (termed PD-L1lo) from parental PD-L1-expressing cell lines and 
made the unexpected observation that PD-L1lo tumor cells proliferated more slowly than 
control cells in vitro, prompting us to study tumor-intrinsic PD-L1 signaling effects in more 
detail. We found that tumor PD-L1 had profound effects on expression of many genes that 
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play important roles in tumor signaling and metabolism, including mammalian target of 
rapamycin (mTOR) and autophagy pathways. Autophagy is a catabolic mechanism utilized 
by tumor cells to modulate cellular stress and metabolism, and is targeted to treat some 
cancers (12). We demonstrated that αPD-L1 antibody used as immunotherapy had 
unexpected, important tumor-specific effects on tumor growth and metastatic spread, and 
that tumor PD-L1 also affected sensitivity to pharmacologic autophagy and mTOR inhibitors 
and cytokines. These data shift the current paradigm regarding the role of PD-L1 effects on 
tumor immunopathogenesis and response to immune checkpoint blockade inhibitory 
antibodies to include tumor-intrinsic signaling consequences, suggest approaches to 
treatment based on tumor PD-L1 status in novel ways and suggest that PD-L1 could be a 
biomarker for treatments other than αPD-L1 or αPD-1.
PD-1, PD-L1 and B7-H3 are all immunoglobulin superfamily members (13), and all regulate 
tumor mTOR (14,15) (and our new data here). Thus, this superfamily appears to have 
common tumor cell-intrinsic effects on important cell signaling and functional outcomes that 
require much additional study. Our work demonstrates additional tumor-intrinsic effects in 
this superfamily, with a focus on PD-L1.
Materials and Methods
Mice
Wild type (WT) C57BL/6J (BL6), βδ TCR knockout (KO), and NOD.Cg-
PrkdcscidIl2rgtm1Wj1/SzJ (non-obese diabetic/severe combined immunodeficiency (NOD/
SCID)/interleukin (IL)-2Rγ KO, NSG) mice were purchased from Jackson Laboratory. PD-
L1 KO mice were a kind gift from Lieping Chen (16). All mice were syngeneic BL6 and 
maintained under specific pathogen free conditions and given food and water ad libitum. 
Age- and sex-matched mice that were at least 8 weeks of age were used for all experiments. 
Only females were used for ID8agg ovarian cancer studies. All animal studies were 
approved by The University of Texas Health Science Center at San Antonio Institutional 
Animal Care and Use Committee.
In vivo tumor challenges, treatments and assessments
Tumor challenge into all mice except NSG was injection of 5 x 105 B16 cells 
subcutaneously as described (16), or 4 x 106 ID8agg cells intraperitoneally. For NSG mice, 
1.5 x 105 B16 or 1 x 106 ID8agg cell challenges were used. B16 growth was measured every 
other day with Vernier calipers and volume calculated as (length x width2)/2. Survival was 
determined as tumor >1500 mm3 or distress (16). ID8agg tumor burden was determined by 
in vivo luciferase imaging and survival was assessed by ascites formation, weight gain or 
distress (17).
αPD-L1 (10F.9G2) and αPD-1 (RMP1-14) antibodies or respective isotype controls were 
injected intraperitoneally. In NSG mouse challenges, we gave 200 μg/mouse every other day 
starting 1 day before tumor challenge. In WT challenge we gave 100 μg/mouse αPD-L1 or 
isotype control every 5 days for B16 or ID8agg cell starting on day 7 after tumor challenge 
for times indicated.
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For pharmacologic autophagy inhibition in vivo, mice were injected intraperitoneally with 
chloroquine 60 mg/kg every other day (18,19) or 3-methyladenine 25 mg/kg every 5 days 
(20) versus PBS control starting on day 7 following tumor challenge, regimens shown to 
inhibit tumor cell autophagy effectively in vivo.
In vivo luciferase detection was performed on an IVIS Lumina (Perkin-Elmer) with 
isoflurane-anaesthetized mice 15 minutes after intraperitoneal injection with 200 μL 
luciferin potassium (15 mg/mL, Gold Biotechnology) with a 30 second exposure. An 
identical region of interest was drawn over each abdomen and tumor burden was quantified 
as average radiance (photons/second/cm2/sr).
Cell lines and transfections
Mouse B16-F10 melanoma (herein “B16” for simplicity) and ID8 ovarian cancer, and 
human ES2 ovarian cancer cells were purchased from the American Type Culture 
Collection. Cells were not revalidated for this work. We generated an aggressive ID8 line, 
ID8agg, by serial passage through WT hosts (Suppl. Fig. 1). Mouse cells were used in 
passages <5 and ES2 was passaged for <6 months. All cells were maintained in 5% fetal 
bovine serum (FBS)-containing RPMI-1640 medium supplemented with 1% penicillin/
streptomycin, 1% L-glutamate, and 1% HEPES buffer. For serum starvation experiments, 
0.1% FBS replaced 5.0%.
Stable PD-L1 knockdown in B16 and ID8agg lines was generated using lentivirus 
transduction particles containing validated PD-L1 shRNA (Sigma, TRCN0000068001) 
against murine Pdcd1Ig1 in pLKO.1-puro vector using puromycin selection per 
manufacturer’s protocol (Suppl. Fig. 2C). Scrambled PD-L1 shRNA control sequence 
(Sigma, SHC216V) was used to generate control lines. Individual PD-L1lo clones were 
selected in 2 μg/ml puromycin. For ES2, PD-L1 shRNA (Sigma, TRCN0000056914) against 
human Pdcd1Ig1 and controls were used as described above. Individual PD-L1lo clones were 
selected in 4 μg/ml puromycin. The PD-L1-overexpressing (PD-L1hi) B16 polyclonal line 
was generated by transfection of pCMV6-PD-L1-GFP plasmid (OriGene, MG203953) using 
Turbofect (ThermoFisher) per the manufacturer’s protocol (Suppl. Fig. 2D). Pooled PD-L1hi 
clones stably expressing PD-L1-GFP were obtained using G418 selection. Luciferase 
expression was engineered into ID8agg cells by transfection with pGL4.51 [luc2/CMV/neo] 
plasmid DNA (Promega) and Attractene transfection reagent (Promega) according to 
manufacturer instructions and individual clones were selected with G418.
Flow cytometry
Cells were stained and sorted as previously described (21), using LSR II and FACSAria 
hardware and analyzed by FACSDiva (BD Bioscience) and FlowJo software (FlowJo, LLC). 
Anti-mouse PD-L1 (10F.9G2), anti-mouse PD-1 (29F.1A12) and matched isotype control 
antibodies were purchased from BioLegend. Cells were treated with recombinant mouse 
interferon (IFN)-γ (0.1 ng/mL, R&D Systems) for 48 hours as noted to induce PD-L1.
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In vitro cell proliferation
Cells (6 x 103) were plated in 96-well plastic culture plates in medium and treated 12 hours 
later with chloroquine (50 μM), 3-methyladenine (5 mM), rapamycin (5 nM) (Sigma for all), 
TNF-α (10 ng/mL; R&D Systems), cisplatin (Sigma; 1–10 μM), or paclitaxel (Sigma; 1–30 
nM). αPD-L1 (10F.9G2) or αPD-1 (RMP1–14) antibodies or respective isotype controls 
were used at 50 μg/mL for the entire culture period. Data shown are from optimized drug 
concentrations in preliminary work not shown. Cell proliferation rates were determined 
using MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide, 5 mg/mL), 
which measures metabolic activity, 72 h after treatment. Absorbance was measured at 540 
nM using a BioTek Synergy 2 Multi-Mode Plate Reader (Winooski, VT). Data are presented 
as mean absorbance versus medium control ± standard error of the mean (SEM). 
Proliferation was assessed in triplicate and compiled from three separate experiments. Cell 
viability was determined using a Vi-Cell XR (Beckman Coulter).
RNA sequencing (RNA-seq)
Total RNA was isolated from control ID8agg and ID8agg PD-L1lo (clone 3) cells using 
RNeasy (Qiagen), and RNA quality was ensured on an Agilent Bioanalyzer. 50 base pair 
single read sequencing was performed using an Illumina HiSeq 2000 system at The 
UTHSCSA Genome Sequencing Facility. Data are presented as gene sequence fold-change 
in PD-L1lo versus control. RNA-seq data was also analyzed by DAVID Bioinformatics and 
corrected for multiple comparisons. Genomic data will be deposited in the Gene Expression 
Omnibus database.
Immunoblotting
Cell lysates were prepared in RIPA buffer (20 mM Tris–HCl pH 8.0, 150 mM NaCl, 1 mM 
disodium EDTA, 1 mM EGTA, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 
1% triton-X100) plus 1 mM phenylmethylsulphonyl fluoride and Halt protease/phosphatase 
inhibitor cocktail (Thermo Scientific). Protein concentration was measured by Bradford 
method (Thermo Scientific). 50 μg protein was separated by 4–15% sodium dodecyl sulfate 
polyacrylamide gels (BioRad Hercules), transferred to PVDF membranes (GE Water and 
Process Technologies), blocked in Tris-buffered saline (pH 7.4) plus 0.1% Tween-20 and 5% 
skim milk, and incubated overnight at 4° C with 1:1000 diluted phospho- and/or total 
antibodies against indicated proteins (Cell Signaling) plus anti-mouse β-actin (Santa Cruz 
Biotechnology). Membranes were incubated with horse radish peroxide-conjugated 
antibodies, 1 h. Proteins were detected by enhanced chemiluminescence (Pierce). Band 
quantification and normalization to total protein was by ImageJ software (22). Data show 
means of 3 individual blots with comparisons only made between like blots from the same 
gels.
Microscopy
Cells were plated at low confluence in 6 well plates (50,000 cells/well). On day 2, cells were 
exposed to serum starvation (0% FBS), normal medium (10% FBS), or chloroquine (50 μM) 
for 24 hours. Medium was removed, cells were washed with PBS and treated with 4% 
paraformaldehyde/PBS for 20 minutes at room temperature, washed, then permeabilized 
Clark et al. Page 5





















with 0.1% Triton X-100 for 10 minutes. Cells were then blocked with 5% normal goat 
serum (Cell Signaling Technology) containing 0.3% Triton X-100 in PBS for 60 minutes. 
Diluted primary antibody, anti-mouse LC3 A/B (Cell Signaling Technology), was applied in 
blocking buffer overnight at 4° C. Alexa Fluor-555 secondary antibody diluted in 1% normal 
goat serum in PBS were added for 1 hour at ambient temperature. Cells were fixed using 
Vectashield hard set mounting medium containing DAPI dye (Vector Laboratories). Images 
were acquired using confocal microscopy (Olympus FV-1000) and overlaid using ImageJ 
(22).
Quantitative RT-PCR
Total RNA was isolated from homogenized whole lung tissue using RNeasy (Qiagen). 
cDNA was synthesized with 1 μg of total RNA using the ImPromII Reverse Transcription 
System (Promega) and random primers. Quantitative PCR (qPCR) was conducted using the 
7900HT Real-Time PCR System (Applied Biosystems), amplified with transcript-specific 
primers with SYBR Green (Thermo Scientific), according to manufacturer’s instructions. 
Mouse primers were: Tyr, 5′-CTCTGGGCTTAGCAGTAGGC-3′ and 5′-
GCAAGCTGTGGTAGTCGTCT-3′; gp100, 5′-ACATTTCATCACCAGCAGGGTGCC-3′ 
and 5′-AACAAGTGGGTGCTGGCC-3′; Trp-2, 5′-GTCCTCCACTCTTTTACAGACG-3′ 
and 5′-ATTCGGTTGTGACCAATGGGT; Trp-1, 5′ CCCCTAGCCTATATCTCCCTTTT-3′ 
and 5′-TACCATCGTGGGGATAATGGC-3′; and Gapdh, 5′-
AACGACCCCTTCATTGAC-3′ and 5′-TCCACGACATACTCAGCAC-3′ as the internal 
control (23).
Statistical analysis
Statistical analyses were conducted with Prizm software (GraphPad). Data in bar graphs are 
means ± SEM. For tumor growth, we used two-way ANOVA plus Bonferroni post-tests to 
compare replicate means. Kaplan-Meier estimates and the log-rank test were used to analyze 
statistical differences in survival. For all other single measurement assays, we used an 
unpaired t test. P<0.05 was considered significant.
Results
ID8agg and B16 express inducible PD-L1
The ID8 ovarian cancer cell line produces tumors that replicate important aspects of human 
disease, including local spread and ascites after intraperitoneal injection into syngeneic BL6 
mice (24) but disease is not manifest for 10–15 weeks (16). We generated an aggressive ID8 
line, ID8agg, by serial passage through WT hosts that produces rapid disease (Suppl. Fig. 1). 
Flow cytometry showed that ID8agg cells express PD-L1 that is upregulated by IFN-γ (Fig. 
1A), and immunoblot and confocal microscopy confirmed PD-L1 expression (Suppl. Fig. 
2A). B16 melanoma cells also express basal PD-L1 that is further upregulated by IFN-γ 
(Fig. 1B, Suppl. Fig. 2B).
Tumor intrinsic PD-L1 regulates ID8agg and B16 cell proliferation in vitro and in vivo
We used plasmids stably expressing shRNA to reduce basal and IFN-γ-inducible PD-L1 
expression (PD-L1lo) in ID8agg and B16 cells, and a constitutively active vector to increase 
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PD-L1 expression in B16 (PD-L1hi, Fig. 1A,B, Suppl. Fig. 2). PD-L1lo B16 cells 
proliferated significantly slower than control B16 cells and PD-L1hi cells exhibited the 
highest rate of proliferation in vitro (Fig. 1C). Subcutaneous WT mouse challenge elicited a 
similar trend, with PD-L1hi B16 cells producing the fastest tumor growth and PD-L1lo cells 
the slowest (not shown). Tumor PD-L1 can inhibit anti-tumor immunity by impeding anti-
tumor CD8+ T cell function (4). Thus, to dissect tumor cell-intrinsic effects versus immune 
effects in vivo, we challenged severely immune-deficient NSG mice with distinct B16 cell 
constructs subcutaneously. Consistent with in vitro and WT challenge data, in the absence of 
tumor-specific immunity, PD-L1hi B16 tumors grew fastest and PD-L1lo tumors grew the 
slowest (Fig. 1D, left), which correlated with reduced overall survival (Fig. 1D, right). 
Further, PD-L1hi cells generated the greatest lung metastases following subcutaneous 
challenge whereas PD-L1lo cells produced the fewest as detected by PCR for tumor-specific 
gene products (Fig. 1E). In support, PD-L1lo ID8agg cells grew more slowly in vitro (Fig. 
1F), and in vivo compared to control ID8agg after intraperitoneal challenge in WT (not 
shown) and NSG mice (Fig. 1G). Together, these data clearly demonstrate that tumor 
intrinsic PD-L1 controls tumor growth in vitro and in vivo in distinct tumors and anatomic 
compartments. PD-L1-mediated growth and promotion of bona fide metastatic tumor spread 
were all independent of anti-tumor immunity.
αPD-L1 retards B16 but not ID8agg tumor growth in NSG mice
To determine if tumor cell proliferation rate is influenced by PD-L1 or PD-1 surface 
expression, we first showed that B16 also expresses PD-1 as reported (15) and found that 
ID8agg also expresses PD-1 (Fig. 2A). Proliferation of control but not PD-L1lo B16 cells in 
vitro was significantly reduced by both αPD-L1 and αPD-1 (Fig. 2B). CD80 was not 
detected (not shown). To assess if αPD-L1 reduces tumor growth in mice lacking anti-tumor 
immunity, we challenged NSG mice with control B16 cells and treated with αPD-L1, which 
reduced control B16 (Fig. 2C) and PD-L1hi B16 growth (Suppl. Fig. 3A), consistent with in 
vitro data. We confirmed that αPD-1 slows control B16 growth in NSG mice (not shown) as 
reported (15). To determine the role of tumor cell-intrinsic PD-L1 in metastatic propensity, 
primary lung metastases in NSG mice challenged subcutaneously with B16 were assessed as 
mRNA of melanoma-specific genes in lung homogenates as described (23). αPD-L1 or 
αPD-1 each reduced B16 lung metastases significantly and similarly (Fig. 2D, Suppl. Fig. 
3B). Similar to B16, αPD-L1 and αPD-1 each reduced rates of control ID8agg cell 
proliferation in vitro, but without significant effect on PD-L1lo ID8agg (Fig. 2E). By 
contrast, αPD-L1 had negligible treatment effects on peritoneal ID8agg cell challenge into 
WT mice (Suppl. Fig. 4), and did not slow tumor growth or improve survival in NSG 
challenge (Fig. 2F,G). Thus, whereas certain PD-L1 signaling effects are similar in distinct 
tumors (and see data to follow), αPD-L1 effects in vivo can be dissociated from in vitro 
effects, as well as from PD-L1 effects in distinct tumors as also seen in lack of αPD-L1 
effects on PD-L1-expressing sarcoma growth in NSG mice (11).
Tumor PD-L1 is the target of αPD-L1-mediated B16 growth inhibition
It is possible that αPD-L1 acts on host PD-L1 to mediate tumor growth inhibition. We first 
showed that αPD-L1 treated control B16, but not PD-L1lo B16 in wild type mice (Suppl. 
Fig. 5A,B). To assess host PD-L1 effects specifically, we showed that αPD-L1 treated 
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parental B16 challenge into PD-L1 KO mice as effectively as in wild type mice, whereas 
αPD-L1 had no effect on PD-L1lo B16 challenge in PD-L1 KO mice (Suppl. Fig. 5C,D). 
Therefore, tumor PD-L1 expression is necessary and sufficient for αPD-L1 effects on B16 
growth in vivo, and host PD-L1 is not required, consistent with anti-proliferative effects in 
vitro (Fig. 2B).
PD-L1 alters tumor-intrinsic signaling
Data thus far clearly indicate a major cell-intrinsic, immune-independent role for tumor PD-
L1 in both ovarian cancer and melanoma cells. We next investigated PD-L1-dependent 
signaling pathways. RNA-seq of control versus PD-L1lo ID8agg cells identified 1269 
differentially expressed basal genes using a 2-fold change cutoff (Fig. 3A and data not 
shown), including significant gene expression differences in canonical and non-canonical 
autophagy pathways (Table 1, top).
Tumor PD-L1 regulates autophagy
We assessed PD-L1 effects on autophagic flux as conversion of LC3-I to LC3-II in parental 
ID8agg or PD-L1lo cells. Serum starvation for 24 hours augmented autophagy in control 
cells as expected. Autophagic flux was significantly higher in basal PD-L1lo versus control 
ID8agg cells as assessed by LC3-II/LC3-I ratio (25) but serum starvation did not increase 
LC3-II further in PD-L1lo cells (Fig. 3B) suggesting that tumor PD-L1 regulates basal and 
starvation-induced autophagy in ID8agg. In support of PD-L1-mediated autophagy 
suppression, LC3 foci formation was lower in control versus PD-L1lo ID8agg (Fig. 3C). PD-
L1 also blunted basal autophagic flux in B16, but in contrast to ID8agg, autophagy was 
significantly induced during serum starvation in PD-L1lo B16 (Fig. 3D), the appropriate 
physiologic response. Consistent with Western blot data, there were more LC3 foci in PD-
L1lo B16 cells indicative of higher autophagosome formation versus control B16 under basal 
conditions and serum starvation (Fig. 3E), consistent with tumor cell PD-L1-mediated 
suppression of autophagy in B16.
PD-L1 sensitizes tumor cells to autophagy inhibitors in vitro
Because PD-L1 depletion deregulates autophagy, including cell-specific effects (Fig. 3B–E), 
we tested effects of the pharmacological autophagy inhibitor chloroquine (18,19). In contrast 
to basal PD-L1 proliferation effects, PD-L1lo B16 cells were the most resistant to in vitro 
chloroquine-mediated proliferation inhibition, whereas PD-L1hi cells were the most sensitive 
(Fig. 4A). Consistent with B16 cell data, PD-L1lo ID8agg cells were significantly more 
resistant to chloroquine-mediated proliferation inhibition versus control ID8agg cells (Fig. 
4A). Using the autophagy inhibitor 3-methyladenine (20), similar, but less pronounced 
proliferation effects were seen in both B16 and ID8agg cells (data not shown).
PD-L1 sensitizes B16 but not ID8agg cells to pharmacologic autophagy inhibitors in vivo
Consistent with in vitro data, chloroquine and 3-methyladenine were significantly more 
effective in reducing control versus PD-L1lo B16 challenge into WT mice (Fig. 4B–D). 
Because autophagy inhibitors could also affect anti-tumor immunity, we assessed effects in 
T cell-deficient βδ TCR KO mice, where chloroquine retained its clinically activity against 
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control B16 (Fig. 4E) and remained ineffective against PD-L1lo (Fig. 4F). Similarly, in NSG 
mice, chloroquine was significantly effective against challenge with control B16 cells (Fig. 
4G), but was ineffective in reducing tumor growth in mice challenged with PD-L1lo B16 
cells (Fig. 4H). Together, these data support the concept that tumor PD-L1 sensitizes B16 
melanoma to autophagy inhibitors independent of T cell immunity, and that tumor PD-L1 
expression predicts autophagy-dependent growth. Consistent with dependence on autophagy 
that modulates cellular stress, serum starvation, which inhibits mTOR signaling and 
constrains cell dependence on autophagy, significantly reduced PD-L1hi and control B16 cell 
viability in vitro under serum starvation conditions (with greatest effect in PD-L1hi cells). 
We found reduced but significant effects in parental B16, and negligible effects in PD-L1lo 
cells (Fig. 4I). By contrast, neither chloroquine nor 3-methyladenine improved survival 
against control or PD-L1lo ID8agg challenge in vivo (Fig 4J). These data further establish 
common and cell-specific PD-L1 signaling effects.
Tumor PD-L1 regulates tumor mTOR signals
mTOR is a serine/threonine kinase regulating cellular growth and metabolism that is 
elevated in many cancers (26,27) and recently shown to be affected by tumor-intrinsic PD-
L1 (11,15). As mTOR regulates important cellular processes including autophagy through 
distinct mTORC1 and mTORC2 complexes with distinct functions (28), we assessed 
additional mTOR signaling details. ID8agg RNA-seq identified potential mTOR signaling 
effects of PD-L1 (Table 1, bottom). For example, the mTORC1 activator Rheb1 was 
significantly lower in PD-L1lo cells (p=5.35x10−7), consistent with reduced mTORC1 
signaling. Prps6, a translation regulator controlled by mTORC1 was also significantly 
reduced (p=7.97x10−7). mTORC2 activity is defined by target phosphorylation and cannot 
be assessed this way.
Tumor PD-L1 regulates mTOR distinctly during serum starvation and treatment and in 
distinct tumors
We used immunoblots to validate that tumor PD-L1 promotes basal mTORC1 signaling as 
assessed by P70S6KT389 phosphorylation (Fig. 5A,B). PD-L1lo ID8agg cells paradoxically 
increased mTORC1 during serum starvation whereas PD-L1lo B16 cells did not (Fig. 5A,B). 
Rapamycin effectively suppressed mTORC1 in control B16 and ID8agg cells as expected 
and equally suppressed mTORC1 in PD-L1lo B16 and ID8agg cells (Fig. 5D, Suppl. Fig. 6). 
PD-L1lo B16 and ID8agg cells were more sensitive to rapamycin-mediated suppression of 
proliferation in vitro versus control cells, by MTT assay (Fig. 5C), suggesting that PD-L1 
regulation of metabolic activity is mTORC1-dependent, although mTORC2 effects cannot 
be excluded (29,30). Under basal conditions PD-L1 inhibited phosphorylation of the 
mTORC2 substrate AktS473 in B16 and ID8agg (Fig. 5A,B), consistent with reduced 
mTORC2 activity (31–33). Rapamycin differentially affected AktS473 phosphorylation in 
B16 versus ID8agg in a PD-L1-dependent manner (Fig. 5D). mTORC1 and phosphorylated 
P70S6KT389 can mediate a negative feedback loop on phosphoinositide 3-kinase (PI3K)/Akt 
(34,35) which is de-repressed by rapamycin. Hence, rapamycin effects on AktS473 
phosphorylation could be mTORC2-independent.
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We next treated cells with chloroquine to inhibit autophagy and found that it inhibited 
mTORC1 as expected (36,37) in control ID8agg but paradoxically increased mTORC1 in 
control B16 cells. Chloroquine had no effect on mTORC1 in PD-L1lo ID8agg cells but 
significantly increased mTORC1 in PD-L1lo B16 cells (Suppl. Fig. 6). Nonetheless, no 
observed mTOR effects readily explain how PD-L1 sensitizes cells to chloroquine-mediated 
cell proliferation inhibition. Thus, PD-L1-mediated mTOR and autophagy effects could be 
independent. Other effects of chloroquine or rapamycin or their combination varied between 
the two tumors based on basal versus serum starvation conditions and PD-L1 status (Fig. 
5D, Suppl. Fig. 6 and much additional data not shown), likely reflecting distinct tumor 
mutational landscapes in ovarian cancer (38) versus melanoma (39) and further supporting 
common versus cell-specific PD-L1 signaling effects. As mTOR and autophagy regulate 
responses to cytotoxic insults including chemotherapy and cytokines (40,41), we explored 
additional effects. Tumor PD-L1 rendered B16 cells resistant to tumor necrosis factor 
(TNF)-α in vitro whereas ID8agg cells were intrinsically more resistant and PD-L1 had no 
effect on TNF-α-mediated cytotoxicity (Suppl. Fig. 7A). Surprisingly, tumor PD-L1 did not 
significantly alter sensitivity of B16 or ID8agg to the cytotoxic agents cisplatin or paclitaxel 
(Suppl. Fig. 7B–C). Thus, tumor PD-L1 is a pro-survival agent, but effects depend on the 
specific toxic insult.
Cell-intrinsic PD-L1 regulates proliferation, mTOR signaling, and autophagy in human 
ovarian cancer cells
To test human relevance, we first showed that the human ES2 ovarian cancer cell line 
expressed basal PD-L1, and then engineered PD-L1lo ES2 cells (Fig. 6A,B). Some ES2 cells 
also express basal PD-1 (Fig. 6B). Consistent with B16 and ID8agg data, PD-L1lo ES2 cells 
proliferated significantly slower than control ES2 (Fig. 6C). LC3-II versus LC3-I was 
increased in PD-L1lo but not in control cells (Fig. 6D), consistent with increased autophagic 
flux when PD-L1 was reduced. In support, LC3 foci were reduced in control versus PD-L1lo 
cells indicative of PD-L1-mediated decrease in autophagosome formation (Fig. 6E). 
Altogether these data are consistent with PD-L1-dependent suppression of autophagic flux 
in human cancer cells, similar to mouse cell data. Further consistent with B16 and ID8agg 
data, PD-L1 in ES2 cells augmented mTORC1 signals (P70S6KT389 phosphorylation). By 
contrast to B16 and ID8agg data, PD-L1 knock down eliminated ES2 mTORC2 activation 
(AktS473 phosphorylation) (Fig. 6F).
Validating our observations in B16 and ID8agg, control ES2 cells were significantly more 
sensitive to proliferation inhibition by chloroquine compared to PD-L1lo ES2 cells (Fig. 6G), 
further suggesting that PD-L1 regulation of cancer cell autophagy and autophagy 
dependence could be a common mechanism in PD-L1 expressing mouse and human cancer 
cells.
Discussion
Tumor-expressed PD-L1 alters tumor immunopathogenesis by delivering negative signals to 
PD-1-expressing anti-tumor T cells (3–7), but emerging evidence shows that PD-L1 and 
PD-1 also have tumor-intrinsic functions (11,15). Our work now clearly establishes that 
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tumor intrinsic PD-L1 has additional, important tumor intrinsic effects. We found that tumor 
PD-L1 promoted cell-intrinsic growth in two distinct tumor types (melanoma and ovarian 
cancer), in distinct anatomic compartments (skin and peritoneum) and in an immune-
independent fashion for both. Thus, these properties are not specific to one single cell type 
or anatomic location.
αPD-L1 can alter PD-L1-mediated cell-intrinsic growth signals as α-PD-L1 slowed B16 
tumor growth in NSG mice incapable of mediating tumor-specific immunity or antibody-
dependent cellular cytotoxicity. Melanoma PD-L1 promoted immune-independent bona fide 
metastases from subcutaneous melanoma, a more stringent model than intravenous cell 
challenge. Increased tumor growth and proliferation likely contributes to increased 
metastases, but additional factors could also contribute. Further work is needed to 
understand applicability to additional cancers and define mechanisms.
αPD-1 and αPD-L1 comparably inhibited B16 growth in vitro, and comparably reduced 
B16 metastases in vivo. These data are consistent with tumor PD-L1/tumor PD-1 
cooperation as only ~5–10% of cells expressed PD-1. In vivo, αPD-L1 effects appears to be 
directed to tumor and not other PD-L1-expressing cells as αPD-L1: i) had no significant 
effect on PD-L1lo B16 melanoma growth in WT mice, and ii) was fully protective in PD-L1 
KO mice challenged with parental B16 cells. However, this treatment effect could be tumor- 
or compartment-specific, as αPD-L1 did not slow tumor growth or improve survival in 
intraperitoneal ID8agg ovarian cancer challenged NSG mice, despite reducing in vitro 
proliferation. In support of tumor-specific effects, a recent report showed that αPD-L1 did 
not slow PD-L1+ sarcoma growth in NSG mice (11). Specific tumors might be refractory to 
PD-L1-driven growth or survival signals owing to tumor-specific mutations (38,39), degree 
of PD-L1 expression, antibody affinity and delivery differences, or other factors.
Tumor PD-L1 suppressed tumor autophagy in melanoma and ovarian cancer, suggesting that 
autophagy disruption could be a relatively general tumor PD-L1 effect. Tumor PD-L1 
regulates glucose metabolism in sarcomas (11), suggesting that PD-L1 could have a variety 
of important cell-intrinsic metabolic effects. Furthermore, B7-H3 regulates glucose 
metabolism in breast cancer cells (42) suggesting that the B7-H superfamily to which PD-L1 
and B7-H3 belong (43) or the immunoglobulin superfamily to which these and PD-1 all 
belong (13), could have important tumor metabolic effects, which is an area meriting 
additional investigations. Our RNA-seq data demonstrated numerous potentially PD-L1-
regulated genes. Ingenuity Pathway Analysis determined that many critical pathways were 
affected, including immune cell trafficking (chemokines and cytokines), inflammation, TGF-
β signalling, metabolism and cancer stem cell genes among others (our unpublished data), in 
addition to effects shown here. Thus, much additional, important PD-L1-mediated tumor cell 
signalling likely awaits definition.
We found that PD-L1-replete B16 melanoma and ID8agg ovarian cancer cells exhibit low 
basal autophagy, with high mTORC1 activity, and were disproportionately sensitive to 
autophagy inhibitor-mediated growth reduction compared to cancer cells with low PD-L1 
expression. We postulate that further autophagy reduction in cancer cells with elevated 
mTORC1 activity and low autophagic activity (directly related to PD-L1 expression), is 
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catastrophic. In support, autophagy levels can be fine-tuned to allow cells to meet metabolic 
demands (44) without compromising other functions. In vivo, this PD-L1-mediated balance 
augments clinical response to autophagy inhibitors. These data suggest that autophagy 
inhibitors could boost αPD-L1 treatment of PD-L1 positive cancers. Despite high levels of 
autophagic flux, PD-L1lo tumor cells might have a reduced autophagy requirement due to 
lower metabolic demand and/or cellular stress, as supported by reduced sensitivity to 
autophagy inhibitors. Furthermore, pharmacologic inhibitors could incompletely inhibit this 
high autophagy for clinical effect. Genetic approaches to autophagy manipulation are 
required to explore mechanisms further, but our data support the thesis that tumor PD-L1 
expression and basal autophagy levels could be a biomarker for effective clinical autophagy 
inhibitor use. Our data also suggest that autophagy inhibition plus αPD-L1 merits clinical 
investigation.
As autophagy is a tumor survival mechanism, we expected that tumor PD-L1 could affect 
cell viability after specific insults, and found differences in survival in serum starvation, 
mTOR and autophagy inhibitors and TNF-α. Surprisingly, though, we did not detect a 
difference in sensitivity to cis-platinum or paclitaxel in vitro. An abstract suggested that 
tumor PD-L1 protects from cytotoxic chemotherapy (10). That work used PD-L1 
overexpression and did not specify cell lines or cytotoxic agents, making us unable to 
comment on potential differences from that work.
PD-L1 regulates tumor mTOR signals in melanoma and sarcoma (11,15), but mechanistic 
details are lacking, and unreported in ovarian cancer. We show that low PD-L1 in melanoma 
and ovarian cancer cells results in reduced phosphorylation of the mTORC1 substrate 
P70S6KT389. PD-L1lo cells proliferated more slowly than control lines, suggesting that 
lower mTORC1 activity in PD-L1lo cells compromises their growth. Proliferation inhibition 
by the (predominantly) mTORC1 inhibitor rapamycin abolished P70S6KT389 
phosphorylation in control and PD-L1lo B16 and ID8agg cells in vitro as expected, yet PD-
L1lo cells were more rapamycin-sensitive than control cells, suggesting that proliferation of 
PD-L1lo tumors is more dependent on basal mTORC1 activity compared to PD-L1-replete 
tumor cells. PD-L1-mediated mTORC1 effects could differ in tumor cell metabolism, 
survival and therapeutic outcomes. Nonetheless, these data support the concept that tumor 
PD-L1-dependent mTORC1 activity drives proliferation. Thus, PD-L1 expression could 
predict mTORC1 activity and rapamycin-sensitive tumor growth, which is clinically 
exploitable. For instance, these data suggest that αPD-L1 and/or αPD-1 immunotherapies 
combined with mTOR inhibitors in treating PD-1/PD-L1-replete tumors, or mTOR 
inhibitors alone in treating PD-1lo/PD-L1lo tumors are rational approaches.
Other mTORC1 substrates, mTORC2 or other rapamycin effects could also mediate specific 
PD-L1-dependent effects. For example, mTORC2 and its substrate Akt drive tumor cell 
growth and survival (45). We found that phosphorylation of the mTORC2 substrate AktS473 
was induced in PD-L1lo B16 and ID8agg cells. In contrast to parental ID8agg cells, 
rapamycin did not further induce pAktS473 in PD-L1lo cells, demonstrating a PD-L1-
dependent effect, perhaps from low basal mTORC1 and P70S6K activities, in which case 
negative feedback on Akt could be inactive and thus unaffected by rapamycin. We speculate 
that PD-L1-driven mTORC1 activation accounts for reduced autophagy, but genetic and 
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additional approaches are required for definitive mechanistic insights. Additional study of 
PD-L1-mediated mTOR signalling and outcomes of mTOR inhibition (e.g. metabolic 
activity), and cell-specific effects could help optimize mTOR inhibition strategies to treat 
selected cancers. As PD-L1, PD-1 and B7-H3 all regulate tumor mTOR signaling 
(11,15,42), this could be another general feature of selected immunoglobulin superfamily 
members and requires additional study.
Finally, we demonstrated human relevance by showing that cell-intrinsic PD-L1 in the 
human ES2 ovarian cancer cell line controls proliferation, mTORC1, autophagic flux and 
sensitivity to autophagy inhibitors. PD-L1 in human melanoma cells controls PD-1 effects 
on melanoma growth and mTOR signals (15). Thus, human studies merit much additional 
attention.
In summary, we show that tumor cell-intrinsic PD-L1 signals mediate effects common to 
melanoma and ovarian cancer cells in mouse lines, and effects extend to human ovarian 
cancer cells. PD-L1 promotes tumor cell proliferation and immune-independent growth in 
melanoma and ovarian cancer cells, and metastatic melanoma spread in vivo. Tumor cell-
intrinsic PD-L1 altered autophagy inhibitor and mTOR inhibitor efficacy. PD-L1 promoted 
basal mTORC1 activation in all cells tested, and inhibited phosphorylation of the mTORC2 
substrate Akt in mouse lines but not the human line tested. αPD-L1 inhibited in vivo 
melanoma growth but not ovarian cancer growth in an immune-independent fashion, and 
melanoma but not ovarian cancer cells were slowed by autophagy inhibitors in vivo. Thus, 
tumor PD-L1 could be a biomarker for response to mTOR or autophagy inhibitors in 
selected cancers. Tumor PD-L1 appeared to cooperate with tumor PD-1 for selected effects. 
As our understanding of tumor cell-intrinsic PD-L1 effects increases, our ability to predict 
treatment responses to various agents and combine them in rationale ways for more effective 
clinical use will improve. Given the extraordinary effect that PD-L1 appears to have on 
diverse, critical cellular processes, much additional work in this area is merited.
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Figure 1. Tumor-intrinsic PD-L1 controls immune-independent growth and metastatic spread
Flow cytometry for PD-L1 expression of in vitro cultured cells. Interferon (IFN)-γ 0.1 
ng/mL added for 48 h as indicated for (A) ID8agg or (B) B16. C. Proliferation in vitro of 
B16 cells determined by MTT versus control (ctrl, set at 100%). p-value, unpaired t test. D. 
NSG mice challenged subcutaneously with indicated B16 cells. P values for tumor size by 
two-way ANOVA and for survival by log-rank test. E. NSG mice challenged with indicated 
B16 cells and sacrificed on day 18. Genes in whole lung lysates by qPCR. p-value, unpaired 
t test. *, p < 0.05, **, p < 0.01. F. Proliferation in vitro of ID8agg cells as in panel C and 
survival in vivo (G) as in panel D after intraperitoneal ID8agg challenge.
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Figure 2. αPD-L1 reduces B16 growth and metastatic spread in NSG mice
A. PD-1 and PD-L1 expression in B16 melanoma and ID8agg ovarian cells measured by 
flow cytometry. B. Proliferation in vitro of B16 cells ± αPD-L1 or αPD-1 (50 μg/mL each) 
determined by MTT versus control (ctrl, set at 100%). p-value, unpaired t test. C. NSG mice 
challenged with indicated B16 cells and treated with αPD-L1 200 μg every other day 
starting one day following challenge. p-value, two-way ANOVA. D. qPCR for indicated 
genes from whole lung lysates from mouse challenged as in C, given αPD-L1 or αPD-1 200 
μg every other day starting on day following challenge, day 18. Unpaired t test. *, p < 0.05, 
**, p < 0.01. E. Proliferation in vitro of ID8agg cells treated as in B. NSG mice challenged 
with ID8agg-luciferase and treated with αPD-L1 200 μg every other day starting one day 
following challenge. P values for average luciferase radiance (F) by two-way ANOVA and 
for survival (G) by log-rank test.
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Figure 3. PD-L1 regulates tumor autophagy genes and functions
A. RNA was isolated from in vitro cultured control or PD-L1lo ID8agg cells and global 
genes were assessed using David Bioinformatics. 5.8E-10, 5.8 x 10−10, etc. B. Western blot 
of lysed ID8agg cells from basal (+) or serum starved (−) (24 h) conditions (left). Right, 
summary data of three independent experiments. p-values, unpaired t test. C. Confocal 
images of autophagosome formation by LC-3 aggregation (red) in control versus PD-L1lo 
ID8agg under basal or serum starved (24 h) conditions. Blue, DAPI for nuclei. D. Analyses 
of B16 cells as in B, (med + or − for basal and serum starved conditions, respectively) 
treated with rapamycin (R) for 16 h, chloroquine (C) for 6 h or both. E. Confocal images of 
autophagosome formation for control versus PD-L1lo B16 as in C.
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Figure 4. Tumor PD-L1 regulates response to pharmacologic autophagy inhibitors
A. Indicated cells were cultured with 50 μM chloroquine and proliferation inhibition (100%-
% proliferation by MTT, with control set at 0%) assessed 72 h later. P values from unpaired t 
test. B-D, wild type mice challenged with indicated cells and treated with chloroquine (CQ) 
or 3-methyladenine (3MA) as described in Materials and Methods. p-values, two-way 
ANOVA. PBS, phosphate buffered saline control. E-F. βδ TCR KO mice challenged and 
treated as in B-D. G-H. NSG mice challenged and treated as in B-D. I. Indicated B16 cells 
from basal (+) or serum starved (−) (24 h) conditions and cell viability normalized to basal 
controls assessed on a Vi-Cell. P values from unpaired t test. J. WT females challenged with 
indicated ID8agg, 4 x 106 cells intraperitoneally, and treated with chloroquine or 3MA as in 
panels B-D. No differences are significant.
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Fig. 5. Tumor PD-L1 regulates mTOR distinctly and blunts rapamycin proliferation inhibition
Summary data of Western blots for P70S6KT389 and AktS473 phosphorylation as ratios of 
phospho-protein to total protein under basal or serum starved (24 h) conditions for ID8agg 
(A) and B16 (B) cells. Statistical analyses from average of three independent experiments. 
C. Indicated cells were cultured with 5 nM rapamycin and proliferation by MTT, with 
control set at 100% assessed 72 h later. D. Representative Western blots for treatments with 
rapamycin (R) for 16 h, chloroquine (C) for 6 h or both (R+C) under basal (+) conditions for 
under serum-starved (−) conditions for ID8agg and B16. Summary data for these blots are in 
Supplemental Fig. 6.
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Fig. 6. Tumor cell-intrinsic PD-L1 regulates proliferation, mTOR signaling, and autophagy in 
human ovarian cancer cells
A. Flow cytometry for PD-L1 expression of in vitro cultured ES2 human ovarian cancer 
cells showing PD-L1 knock-down by shRNA. B. PD-1 and PD-L1 expression by flow 
cytometry. C. Proliferation in vitro of ES2 cells determined by MTT versus control (ctrl, set 
at 100%). p-value, unpaired t test. D. Western blot for LC3I/II in ES2 cell lysates from basal 
conditions. E. Confocal images of autophagosome formation by LC-3 aggregation (red) in 
control versus PD-L1lo ES2 under basal or serum starved (24 h) conditions. Blue, DAPI for 
nuclei. F. Western blot for P70S6KT389 and AktS473 phosphorylation in ES2 cells under 
basal conditions. G. Control and PD-L1lo ES2 cells were cultured with 50 μM chloroquine 
and proliferation inhibition (100%-% proliferation by MTT, with control set at 0%) assessed 
72 h later. P-values, unpaired t test.
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Table 1
Selected genes from RNA-seq analyses of control and PD-L1lo ID8agg, as ratio of gene expression in PD-L1lo 
versus control cells. Top, autophagy pathway genes. Bottom, mTOR pathway signaling genes.
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